4.1.4.3. surgical management. 4.1.4.3.1. bladder wall injection botulinum toxin onabotulinumtoxina (onabota; botox®) 100 u licenced europe treat oab persistent refractory uui adults sexes . surgeons aware doses onabota formulations botulinum toxin a, abobotulinumtoxin incobotulinumtoxin a, licensed use oab/uui. doses onabota transposable brands onabotulinumtoxina. continued efficacy repeat injections usual, discontinuation rates may high . important adverse events related onabota 100 u injection detected regulatory trials uti increase pvr volume may require cisc . sr included ten studies 2,055 patients comparing intravesical onabota injection placebo. onabotulinumtoxina effective placebo improvement mean symptoms score, reduction mean urgency episodes, mean uui episodes, mean frequency episodes, mean nocturia episodes . statistically significant difference found onabota placebo change mean voided volumes maximum cystometric capacity. onabotulinumtoxina associated significantly higher rates voiding dysfunction compared placebo 100 unit dose 200 unit dose, significantly higher rates uti 100-unit dose 200-unit dose. cochrane review reported significant difference pvr volume onabota placebo groups . quality life substantially improved onabota arm, shown > 2.5 times improvement incontinence quality life questionnaire (i-qol) scores compared baseline. cohort studies shown effectiveness bladder wall injections onabota elderly frail elderly people , although success rate might lower pvr volume (> 150 ml) higher group. median time request retreatment pooled analysis two rcts 24 weeks . follow-up 3.5 years showed consistent increasing duration effect subsequent treatment, median 7.5 months. considerable differences noted patients’ outcomes secondary analysis . two rcts 545 patients compared onabota injections antimuscarinics. onabotulinumtoxina significantly effective curing uui, significant difference noted reduction mean uui episodes. however, associated significantly higher rates voiding dysfunction antimuscarinics, utis . identification urodynamics appear influence outcome onabotna injections patients uui . 4.1.4.3.1.1. summary evidence recommendations bladder wall injection onabotulinumtoxina summary evidencelea single treatment session onabota (100 u) injected bladder wall effective placebo curing improving uui/oab symptoms improving qol.1athere evidence repeated injections onabota reduced efficacy, discontinuation rates high.2athere risk voiding dysfunction, increased pvr volume uti onabota injections.1athe risk bacteriuria onabota (100 u) injection high clinical significance remains uncertain.1bonabotulinumtoxina effective curing uui similarly effective reducing mean uui episodes compared antimuscarinics.1aonabotulinumtoxina associated higher rates voiding dysfunction antimuscarinics.1a recommendationsstrength ratingoffer bladder wall injections onabotulinumtoxina (100 u) patients oab/uui refractory conservative therapy drug treatment.strongwarn patients limited duration response, risk uti possible prolonged need clean intermittent self-catheterisation prior offering treatment onabotulinumtoxina.strong 4.1.4.3.2. sacral nerve stimulation sacral nerve stimulation (sns) involves placing electrodes adjacent sacral nerve roots delivering electric current area via attached battery implanted buttock. delivers low-amplitude stimulation resulting modulation neural activity stabilisation bladder electrical activity mechanism is, yet, fully understood. centres, test stimulation temporary permanent electrode performed assess response, undertaking permanent stimulator implantation. currently, reliable predictor treatment success sns test stimulation. sr find predictive factors success due low level evidence included studies (small, retrospective, heterogeneous populations) . randomised studies suffer limitation patients cannot blinded treatment allocation since recruited patients respond test phase randomisation. rosetta trial randomised 386 women refractory uui sns (n = 194 women) intradetrusor injection onabota (n = 192 women) . two years, authors found statistically significant difference sns onabota improvement mean symptom scores oabq-sf reducing mean uui daily episodes. patients reported significantly higher satisfaction onabota, also significantly higher rates recurrent utis sns (24% vs. 10%, respectively). hand, sns associated 9% removal rate 3% revision rate two-years follow-up. insite trial randomised 70 (94% women) patients sns implantation 77 patients (92% women) receive antimuscarinics . six months follow-up, results showed statistically significant higher success rate sns compared antimuscarinics – success defined > 50% improvement daily uui frequency episodes. adverse events occurred 30% 27% sns antimuscarinics trial arms, respectively, none serious. sns associated higher rates utis associated implant site infection lead migration 3.4% cases each. cochrane review identified three rcts investigated sns patients refractory uui. majority studies compared strategy immediate implantation delayed implantation. one study compared implantation controls stayed medical treatment received delayed implantation six months. fifty percent immediately implanted group > 90% improvement uui six months compared 1.6% control group . effect qol measured sf-36, unclear differed groups one eight dimensions. rct achieved similar results, although patients already included first report . another sr studies including sns > 6 months follow-up reported dry rates 43–56% . adverse events occurred 50% implanted cases, surgical revision necessary 33–41% . sub-analysis rct similar success rates found patients without urodynamic . 4.1.4.3.2.1. summary evidence recommendation sacral nerve stimulation summary evidencelesacral nerve stimulation effective continuation failed conservative treatment oab/uui, sham controls used.1bsacral nerve stimulation effective onabota 200 u injection 24 months.1bin patients implanted, 50% improvement uui maintained > 50% patients 15% may remain cured four years.3 recommendationstrength ratingoffer sacral nerve stimulation patients overactive bladder/urge urinary incontinence refractory anticholinergic therapy.strong 4.1.4.3.3. laser treatment recent sr evaluated use vaginal lasers treatment oab short term studies detailing minimal improvement . rcts included, quality reported studies weak long-term safety data also lacking. 4.1.4.3.3.1. summary evidence recommendation laser treatment summary evidencelevaginal laser therapy shows minimal oab symptom improvement short term, minimal complications, however, long-term efficacy safety data lacking.3 recommendationstrength ratingdo offer vaginal laser therapy treat overactive bladder symptoms outside well-regulated clinical research trial.strong 4.1.4.3.4. cystoplasty/urinary diversion 4.1.4.3.4.1. augmentation cystoplasty augmentation cystoplasty (also known clam cystoplasty), detubularised segment bowel inserted bivalved bladder wall. evidence pertaining cystoplasty comes patients neuropathic bladder dysfunction. one study find difference bivalving bladder sagittal coronal plane . procedure done, equal success open robotic techniques, although latter takes time . rcts comparing bladder augmentation treatments patients oab/uui. large case series bladder augmentation mixed population idiopathic neurogenic uui included 51 women . average follow-up 74.5 months, 53% continent satisfied surgery, whereas 25% occasional leaks 18% continued disabling uui. results idiopathic (58%) less satisfactory neurogenic uui (90%). malignant transformation reported series; however, documented series sr [265-267]. fewer 60 cases reported worldwide, almost exclusively beyond ten years original cystoplasty . adverse effects common summarised review five seventeen years follow-upof > 267 cases; 61 non-neurogenic uui . short-term complications include bowel obstruction (2%), infection (1.5%), thromboembolism (1%), bleeding (0.75%) fistula (0.4%). long term, patients may require cisc obtain adequate bladder emptying (38%). long-term effects include asymptomatic bacteriuria (70%), changes bowel symptoms (25%), uti (20%), metabolic disturbances (16%), urinary tract stones (13%), deterioration renal function (2%), bladder perforation (0.75%). unclear mucolytic agents reduce mucus accumulation. rct comparing various mucolytic agents find significant benefits use n-acetylcysteine, aspirin, ranitidine. one small study (n = 40), subcutaneous octreotide immediately before, fifteen days surgery yielded significant reductions mucus production, need bladder irrigation clear blockages, mean duration hospital stay . cystoplasty, potential complications outlined, surgery, patients well supported stoma/continence nurses. depending relative costs onabota augmentation cystoplasty, latter cost-effective within 5 years complication rate low duration effect onabota < 5 months . 4.1.4.3.4.2. detrusor myectomy (bladder auto-augmentation) detrusor myectomy aims increase bladder capacity reduce storage pressure incising excising portion detrusor muscle, create bladder mucosal bulge pseudo-diverticulum. initially described alternative bladder augmentation children . two case series adult patients idiopathic neurogenic bladder dysfunction demonstrated poor long-term results caused fibrosis pseudo-diverticulum . technique rarely, ever, used nowadays. 4.1.4.3.4.3. urinary diversion urinary diversion remains reconstructive option patients intractable ui multiple pelvic procedures, radiotherapy pelvic pathology leading irreversible sphincteric incompetence fistula formation. options include ileal conduit urinary diversion, orthotopic neobladder heterotopic neobladder mitrofanoff continent catheterisable conduit. insufficient evidence comment procedure leads improved qol. small study comparing ileal colonic conduits concluded differences relative risks (rr) uut infection uretero-intestinal stenosis. however, studies specifically examined techniques treatment intractable oab/uui . therefore, careful consideration operation undertaken depends thorough preoperative counselling, access stoma/continence nurses, well patient factors allow fully informed patient choice. 4.1.4.3.4.4. summary evidence recommendations cystoplasty/urinary diversion summary evidencelethere limited evidence effectiveness augmentation cystoplasty urinary diversion specifically treatment idiopathic oab uui.3augmentation cystoplasty urinary diversion associated high risks short- long-term severe complications.3the need perform cisc following augmentation cystoplasty common.3there evidence comparing efficacy adverse effects augmentation cystoplasty urinary diversion.3 recommendationsstrength ratingensure patient counselling life-long support prior major surgery treatment overactive bladder (oab) provided specialist nurse equivalent health care provider.strongoffer augmentation cystoplasty patients oab/urge urinary incontinence (uui) failed treatment options informed possible complications.weakinform patients undergoing augmentation cystoplasty high risk clean intermittent self-catheterisation (ensure willing able so) need life-long surveillance.strongdo offer detrusor myectomy treatment uui.weakonly offer urinary diversion patients failed less-invasive therapies treatment oab/uui, accept stoma warned possible small risk malignancy.weak